The significant revenue growth and raised guidance suggest strong commercial momentum. The upcoming clinical catalysts, particularly the Q2 2026 topline data for volixibat in PSC, could be major value drivers. The increased cash position provides runway for pipeline advancement.
MIRM drugs
MIRM drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 26 $92.19entry
- T+1 · 9mo ago +0.11%α +0.59% · $92.29
- T+5 · 9mo ago −4.72%α −3.56% · $87.84
- T+20 · 8mo ago −3.59%α +2.82% · $88.88
- T+60 · 6mo ago +6.97%α −1.20% · $98.62
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Mirum Pharmaceuticals reported strong 2025 financial results with $521.3 million in net product sales, representing 55% year-over-year growth. The company raised its 2026 guidance to $630-$650 million in global net product sales and highlighted four upcoming clinical catalysts, including topline data for volixibat in PSC expected in Q2 2026.
Key Financial Metrics
Key Facts
- 2025 net product sales of $521.3 million, up 55% YoY from $336.4 million in 2024
- 2026 guidance raised to $630-$650 million in global net product sales
- LIVMARLI net sales reached $360.0 million in 2025, up 69% YoY
- Bile Acid Medicines net sales reached $161.3 million in 2025, up 31% YoY
- Unrestricted cash, cash equivalents and investments increased to $391.4 million as of December 31, 2025
- Four potentially registrational readouts expected over the next 18 months, starting with volixibat VISTAS study in PSC in Q2 2026
Financial Impact
2025 revenue of $521.3 million (55% YoY growth) with 2026 guidance of $630-$650 million
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| LIVMARLI | $360.0M | +69.0% |
| Bile Acid Medicines | $161.3M | +31.0% |
Risk Factors
- Increased operating expenses from $424.5 million in 2024 to $543.4 million in 2025
- Continued net losses, though improving from $87.9 million in 2024 to $23.4 million in 2025
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001759425-26-000010 |
| Document: mirm-20260225.htm | 0001759425-26-000010 |
| Document: 0001759425-26-000010-index-headers.html | 0001759425-26-000010 |
| Document: 0001759425-26-000010-index.html | 0001759425-26-000010 |
| Document: 0001759425-26-000010.txt | 0001759425-26-000010 |
Track record
27 reports on MIRM
4 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +28.29% at T+20 after the Jun 11, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $92.28 Now $91.58 −0.76% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 3/10 Entry $93.54 Now $91.58 −2.10% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $93.33 Now $91.58 −1.88% settles Feb 10
- Nov 10, 20266d ago 8-K Bullish 6/10 Entry $94.42 Now $91.58 −3.01% settles Feb 8
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $96.97 Now $91.58 −5.56% settles Feb 2
- Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $85.81 Now $91.58 +6.72% settles Jan 26
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $85.56 Now $91.58 +7.04% settles Jan 25
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $79.62 Now $91.58 +15.02% settles Jan 8
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers